Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC and Liberation Therapy in RRMS
NCT02418325Phase 2Terminated
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic human umbilical cord tissue-derived mesenchymal stem cells in relapsing-remitting multiple sclerosis (RRMS). Started Feb 2015; status: terminated.
02
Drugs
allogeneic human umbilical cord tissue-derived mesenchymal stem cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02418325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418325.